Open Access
Numéro
Cah. Myol.
Numéro 19, Juin 2019
Page(s) 49 - 56
Section Journée Pompe 2019 / Pompe Disease Day 2019
DOI https://doi.org/10.1051/myolog/201919020
Publié en ligne 5 juillet 2019
  1. Elenga N, Verloes A, Mrsic Y, et al., Incidence of infantile Pompe disease in the Maroon population of French Guiana. BMJ Paediatr Open. 2018 ; 2 : e000182. [CrossRef] [PubMed] [Google Scholar]
  2. Papadimas GK, Spengos K, Konstantinopoulou A, et al., Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy. Clin Neurol Neurosurg. 2011 ; 113 : 303–7. [CrossRef] [PubMed] [Google Scholar]
  3. Terzis G, Dimopoulos F, Papadimas GK, et al., Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab. 2011 ; 104 : 279–83. [Google Scholar]
  4. Terzis G, Krase A, Papadimas G, et al., Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab. 2012 ; 107 : 669–73. [Google Scholar]
  5. Papadimas GK, Terzis G, Methenitis S, et al., Body composition analysis in late-onset Pompe disease. Mol Genet Metab. 2011 ; 102 : 41–3. [Google Scholar]
  6. Semplicini C, Letard P, De Antonio M, et al., Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study. J Inherit Metab Dis. 2018 ; 41 : 937–46. [CrossRef] [PubMed] [Google Scholar]
  7. van der Beek NA, Hagemans ML, van der Ploeg AT, et al., The Rasch-built Pompe-specific activity (R-PAct) scale. Neuromuscul Disord. 2013 ; 23 : 256–64. [CrossRef] [PubMed] [Google Scholar]
  8. Scheidegger O, Leupold D, Sauter R, et al., 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe registry. J Neurol. 2018 ;265 : 2783–8. [CrossRef] [PubMed] [Google Scholar]
  9. Stepien KM, Hendriksz CJ, Roberts M, et al., Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years. Mol Genet Metab. 2016 ; 117 : 413–8. [Google Scholar]
  10. Lagalice L, Pichon J, Gougeon E, et al., Satellite cells fail to contribute to muscle repair but are functional in Pompe disease (glycogenosis type II). Acta Neuropathol Commun. 2018 ; 6 : 116. [Google Scholar]
  11. Slingerland NW, Polling JR, van Gelder CM, van der Ploeg AT, Bleyen I, Ptosis, extraocular motility disorder, and myopia as features of Pompe disease. Orbit. 2011 ; 30 : 111–3. [CrossRef] [PubMed] [Google Scholar]
  12. Ravaglia S, Bini P, Garaghani KS, Danesino C, Ptosis in Pompe disease: common genetic background in infantile and adult series. J Neuroophthalmol. 2010 ; 30 : 389–90. [Google Scholar]
  13. Yanovitch TL, Banugaria SG, Proia AD, Kishnani PS, Clinical and histologic ocular findings in Pompe disease. J Pediatr Ophthalmol Strabismus. 2010 ; 47 : 34–40. [Google Scholar]
  14. Toussaint D, Danis P, Ocular histopathology in generalized glycogenosis (Pompe’s disease). Arch Ophthalmol. 1965 ; 73 : 342–9. [CrossRef] [PubMed] [Google Scholar]
  15. Armour SM, Nordin J, Puzzo F, et al., Safety and efficacy evaluation of investigational liver gene transfer for secretable GAA in the treatment of Pompe disease. Mol Genet Metab. 2019 ; 126 : S24. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.